Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.47 |
| ▸ | DPYD | Q12882 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | THPO | P40225 | 1/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HBB | P68871 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190858 | 0.80 | ALDH1A1 (0.47) | ATAD2DPYDGAAALDH1A1LMNA | |
| SCHEMBL161148 | 0.79 | ATAD2 (0.54) | ATAD2DPYDGAAALDH1A1LMNA | |
| SCHEMBL4353311 | 0.76 | DPYD (0.50) | ATAD2DPYDGAAALDH1A1LMNA | |
| SCHEMBL5800398 | 0.76 | — | — | |
| SCHEMBL156784 | 0.73 | ATAD2 (0.48) | ATAD2 | |
| SCHEMBL3485396 | 0.73 | ATAD2 (0.44) | ATAD2DPYD | |
| SCHEMBL6555485 | 0.72 | DPYD (0.52) | ATAD2DPYDGAAALDH1A1LMNA | |
| SCHEMBL1916592 | 0.72 | DPYD (0.46) | ATAD2DPYDGAAALDH1A1LMNA | |
| SCHEMBL5798297 | 0.72 | DPYD (0.46) | ATAD2DPYDGAAALDH1A1LMNA | |
| SCHEMBL2584919 | 0.72 | LMNA (0.52) | ATAD2DPYDGAAALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170360740-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2017-12-21 | — | — | US | disclosed |
| US-9724321-B2 | Histone deacetylase inhibitors | PRESIDENT & FELLOWS OF HARVARD COLLEGE (US) | 2017-08-08 | — | — | US | disclosed |
| US-20160143874-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2016-05-26 | — | — | US | disclosed |
| US-20140213620-A1 | HISTONE DEACETYLASE INHIBITORS | BRADNER JAMES ELLIOT (US) | 2014-07-31 | — | — | US | disclosed |
| US-8754237-B2 | Bifunctional histone deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2014-06-17 | — | — | US | disclosed |
| US-8383855-B2 | Histone deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-02-26 | — | — | US | disclosed |
| US-20130018103-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-01-17 | — | — | US | disclosed |
| US-8304451-B2 | Histone deacetylase and tubulin deacetylase inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-11-06 | — | — | US | disclosed |
| US-8222423-B2 | Bifunctional histone deacetylase inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2012-07-17 | — | — | US | disclosed |
| US-8178579-B2 | Histone deacetylase inhibitors; anticancer agents; antiprotozoa agents | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2012-05-15 | — | — | US | disclosed |
| US-7902373-B2 | asthma; for treating prostaglandin D2 mediated diseases; e.g. 6-(3-fluorophenyl)-N-[1-(1-methyl-1H-tetrazol-5-yl)piperidin-4-yl]nicotinamide | PFIZER INC (US) | 2011-03-08 | — | — | US | disclosed |
| US-20100093842-A1 | Laulimalide Analogs and Uses Thereof | EISAI CO. LTD. | 2010-04-15 | — | — | US | disclosed |
| US-20100056588-A1 | HISTONE DEACETYLASE INHIBITORS | DANA-FARBER CANCER INSTITUTE, INC. | 2010-03-04 | — | — | US | disclosed |
| US-20090312363-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-12-17 | — | — | US | disclosed |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2009-08-20 | — | — | US | disclosed |
| US-20080269245-A1 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2008-10-30 | — | — | US | disclosed |
| US-20080146569-A1 | Nicotinamide Derivatives | PFIZER INC. | 2008-06-19 | — | — | US | disclosed |
| US-20070287745-A1 | Laulimalide Analogs and Uses Thereof | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2007-12-13 | — | — | US | disclosed |
| US-7244853-B2 | Dioxanes and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2007-07-17 | — | — | US | disclosed |
| US-20040072849-A1 | Dioxanes and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2004-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130018103-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC2 | ATAD2 376/4885DPYD 499/4885GAA 892/4885 |
| US-20100093842-A1 | Laulimalide Analogs and Uses Thereof | LPXN, MLX, ZYX | ATAD2 4363/4885DPYD 730/4885GAA 11/4885 |
| US-20140213620-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | ATAD2 2072/4885DPYD 1027/4885GAA 363/4885 |
| US-20160143874-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | ATAD2 2336/4885DPYD 1409/4885GAA 537/4885 |
| US-20090312363-A1 | BIFUNCTIONAL HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC2 | ATAD2 376/4885DPYD 499/4885GAA 892/4885 |
| US-20090209590-A1 | Histone Deacetylase and Tubulin Deacetylase Inhibitors | HDAC6, HDAC1, HDAC5 | ATAD2 118/4885DPYD 1195/4885GAA 440/4885 |
| US-20170360740-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | ATAD2 2072/4885DPYD 1027/4885GAA 363/4885 |
| US-20040072849-A1 | Dioxanes and uses thereof | UTS2R, HDAC5, AMDHD2 | ATAD2 681/4885DPYD 300/4885GAA 220/4885 |
| US-20070287745-A1 | Laulimalide Analogs and Uses Thereof | LPXN, MLX, ZYX | ATAD2 4363/4885DPYD 730/4885GAA 11/4885 |
| US-20080146569-A1 | Nicotinamide Derivatives | NNT, NAMPT, NADK | ATAD2 2903/4885DPYD 74/4885GAA 1059/4885 |
| US-20100056588-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC7 | ATAD2 2072/4885DPYD 1027/4885GAA 363/4885 |
| US-20080269245-A1 | Dioxanes and uses thereof | UTS2R, MAN2B2, AMDHD2 | ATAD2 598/4885DPYD 310/4885GAA 299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.